I’ve spent eleven years sitting in the back of conference rooms, tracking who is actually in the seats and whether the content moves the needle on formulary access. Most of the time, the answer is no. If you’re a commercial operations lead or a managed markets director, you’ve heard the same tired pitches: "We offer great networking opportunities."
Networking is not a strategy. Networking is just a room full of people hoping to sell each other something. If you want to talk about value-based care and outcomes-based agreements, you need to be surgical about where you invest your travel budget.
My running spreadsheet—the one I keep to track who I actually meet—tells a very different story than the glossy brochures promise. Here is the reality check on the major players in the space and whether they actually deliver on the heavy-hitting topics of reimbursement and market access.
Market Access vs. Prescriber Reach: Know the Difference
Before looking at the calendar, acknowledge the distinction. Prescriber reach is about convincing a doctor to write the script. Market access is about ensuring the pharmacy is allowed to fill it. Most conferences blur this line, filling their agenda with "clinical insights" while ignoring the structural barriers set by health system formulary committees and HTA-driven payer boards.
If a conference agenda focuses on "patient advocacy" and "brand awareness," it isn’t a market access conference. It’s a marketing conference. Real market access content Learn more here should feel dry, technical, and slightly uncomfortable because it deals with the reality of pricing, affordability, and the messy mechanics of data sharing.. Exactly.
The Big Three: Where You Should Be
I track three major organizations because they attract the decision-makers who actually handle the budget: AMCP (Academy of Managed Care Pharmacy), The Health Management Academy (THMA), and the Association of Cancer Care Centers (ACCC).
AMCP: The Technical Deep Dive
AMCP is the gold standard for pharmacy-level managed care strategy. If you are trying to understand how outcomes-based agreements are being structured in the real world, this is the room. They don't just talk about the theory; they talk about the data requirements and the digital tools needed to track evidence generation.
The Reality Check: The sessions can be incredibly granular. If you aren't prepared to discuss the limitations of your evidence generation platform, you will get eaten alive during Q&A.
The Health Management Academy (THMA): C-Suite Strategy
THMA is where you go for health system adoption. These executives aren’t interested in your brand’s "synergy." They are interested in HTA pressure, margin preservation, and how your drug fits into their internal value-based care initiatives. They want to know if your product reduces total cost of care or if it just creates a new budget line item they can't afford.
ACCC: The Tactical Intersection
For those in oncology or complex therapeutics, the ACCC is the bridge between clinical care and billing. This is where you see the implementation of formulary execution at the site level. If you want to know why a cancer center is rejecting your pre-authorization protocol, you find the answer here.
Comparison Table: Where to Focus Your Budget
Organization Best For Value-Based Care Depth Primary Audience AMCP Pharmacy Policy & Contracting High (Contract-focused) P&T Committee members, Pharmacy Directors THMA Health System Strategy High (Macro-economic focus) Health System Execs, C-Suite ACCC Operational Reality Medium (Site-level implementation) Oncology Practice Managers, Billing LeadsPricing, Affordability, and the HTA Pressure
Let’s be blunt: if a conference avoids the topic of pricing, it is a waste of time. Payer strategy sessions at these events should be focused on how we prove value in a world where HTA bodies are becoming increasingly aggressive.
You know what's funny? we are seeing a move toward digital tools in evidence generation that can track real-time patient outcomes. These tools are the foundation for any successful outcomes-based agreement. If the speakers at your chosen conference aren't discussing how these digital platforms integrate with PBM and payer claims data, they are operating five years in the past.
I find it ironic that while we demand sophisticated digital evidence generation to prove value, we often browse conference sites that are cluttered with poorly implemented UI elements—like the standard Cookie Law Info plugin pop-ups that force users to click "accept" before they can even read the agenda. It is a microcosm of our industry: we want data-driven precision, yet we accept clunky, barrier-ridden experiences as the status quo.
The Monday Morning Reflection
Every time I leave a conference, I ask myself the same question: "What would I do differently on Monday?"
If you attend an market access planning for 2026 launches event and your only takeaway is a stack of business cards and a "better understanding of the landscape," you failed. Here is how to actually get value from these events:
Identify the Decision Maker: Don’t network with your peers. Network with the people who manage the formulary access at a major health system. If they aren't there, you're at the wrong event. Bring Real Evidence Questions: Instead of "What do you think about outcomes contracts?", ask "What specific data points does your HTA committee require to approve a risk-sharing agreement for a new specialty drug?" Document the "Actually Met" list: Keep your own spreadsheet. Note who actually has authority over budget vs. who is just a middle-manager attending for the CPE credits.
Conclusion: Stop Looking for "Synergy," Start Looking for Data
Value-based care is not a buzzword to be thrown around in a pitch deck. It is a financial framework that requires a massive lift in evidence generation, digital integration, and contractual flexibility. If a conference isn't challenging you on the technical aspects of these contracts, they are selling you a dream that doesn't exist in the current managed care environment.
Be skeptical of the agendas. Look for the technical tracks. And most importantly, track who you talk to. If you leave a conference and you haven’t had a conversation that makes you rethink your pricing or your outcomes strategy, don't go back next year. There are better ways to spend your budget.